Evidence map›Paper›PMID 36964320›Full record

ArticlePsychopharmacology2023

Genetic effects in a progressive model of parkinsonism induced by reserpine.

Guilherme Pasetto Fadanni, Anderson Henrique França Figueiredo Leão, Natalli Granzotto, Aline Guimarães Pereira, Auderlan Mendonça de Gois, Pâmela Andressa Ramborger Anjos, Áurea Elizabeth Linder, José Ronaldo Santos, Regina Helena Silva, Geison Souza Izídio

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Guilherme Pasetto FadanniGraduate Program of Pharmacology, Center of Biological Sciences, Universidade Federal de Santa Catarina, Florianópolis, Brazil.
Anderson Henrique França Figueiredo LeãoDepartment of Pharmacology, Universidade Federal de São Paulo, São Paulo, Brazil.
Natalli GranzottoGraduate Program of Pharmacology, Center of Biological Sciences, Universidade Federal de Santa Catarina, Florianópolis, Brazil.
Aline Guimarães PereiraGraduate Program of Developmental and Cellular Biology, Center of Biological Sciences, Universidade Federal de Santa Catarina, Florianópolis, Brazil.
Auderlan Mendonça de GoisLaboratory of Behavioral and Evolutionary Neurobiology, Department of Biosciences, Universidade Federal de Sergipe, Itabaiana, Brazil.
Pâmela Andressa Ramborger AnjosGraduate Program of Pharmacology, Center of Biological Sciences, Universidade Federal de Santa Catarina, Florianópolis, Brazil.
Áurea Elizabeth LinderGraduate Program of Pharmacology, Center of Biological Sciences, Universidade Federal de Santa Catarina, Florianópolis, Brazil.
José Ronaldo SantosLaboratory of Behavioral and Evolutionary Neurobiology, Department of Biosciences, Universidade Federal de Sergipe, Itabaiana, Brazil.
Regina Helena SilvaDepartment of Pharmacology, Universidade Federal de São Paulo, São Paulo, Brazil.
Geison Souza IzídioGraduate Program of Pharmacology, Center of Biological Sciences, Universidade Federal de Santa Catarina, Florianópolis, Brazil. geisonizidio@gmail.com.ORCID http://orcid.org/0000-0001-7406-2923
Universidade Federal de Santa Catarina · BRUniversidade Federal de São Paulo · BRUniversidade Federal de Sergipe · BR

Funding

conselho nacional de desenvolvimento científico e tecnológico Edital MCT/CNPq 14/2010conselho nacional de desenvolvimento científico e tecnológico Grant 303325/2017-8conselho nacional de desenvolvimento científico e tecnológico MCTI/CNPq 14/2013coordenação de aperfeiçoamento de pessoal de nível superior PNPD/CAPESfundação de amparo à pesquisa do estado de são paulo Grant 2015/12308-5
6 · The paper itself

Abstract

OBJECTIVE AND

methodsWe investigated the locomotor, emotional, physiological, and neurobiological effects induced by low-dose reserpine repeated treatment (0.1 mg/kg; 14 injections) in males from the Lewis (LEW), Spontaneously Hypertensive Rats (SHR), and SHR.LEW-(D4Rat76-D4Mgh11) (SLA16) isogenic rat strains, which have different genetic backgrounds on chromosome 4. Behavioral responses in the catalepsy, open-field, and oral movements' tests were coupled with blood pressure, body weight, and striatal tyrosine hydroxylase (TH) level assessments to establish neurobiological comparisons between reserpine-induced impairments and genetic backgrounds

resultsResults revealed the SHR strain was more sensitive in the catalepsy test and exhibited higher TH immunoreactivity in the dorsal striatum. The SLA16 strain presented more oral movements, suggesting increased susceptibility to develop oral dyskinesia.

conclusionsOur results showed the efficacy of repeated treatment with a low dose of reserpine and demonstrated, for the first time, the genetic influence of a specific region of chromosome 4 on the expression of these effects.

Indexed as

Parkinsonian DisordersReserpineAnimalsBehavior, AnimalCatalepsyMaleRatsRats, Inbred LewRats, Inbred SHRReserpineBlood pressureOral dyskinesiaParkinson’s diseaseSHRTyrosine hydroxylase

Identifiers

PMID36964320
OpenAlexW4360828786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.